Filing Details
- Accession Number:
- 0001213900-25-010195
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-04 19:41:43
- Reporting Period:
- 2025-01-29
- Filing Date:
- 2025-02-04
- Accepted Time:
- 2025-02-04 19:41:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 2028614 | Drugs Made In America Acquisition Corp. | DMAA | Blank Checks (6770) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 2038492 | Drugs Made In America Acquisition Llc | 1 East Broward Boulevard, Suite 700 Fort Lauderdale FL 33301 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2025-01-29 | 400,000 | $0.00 | 10,257,143 | No | 4 | P | Direct | |
| Ordinary Shares | Disposition | 2025-01-29 | 400,000 | $0.00 | 9,857,143 | No | 4 | J | Direct | |
| Ordinary Shares | Disposition | 2025-01-29 | 5,698,363 | $0.00 | 4,158,780 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | J | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Rights to receive ordinary shares | Acquisiton | 2025-01-29 | 400,000 | $0.00 | 400,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 400,000 | No | 4 | P | Direct |
Footnotes
- Reflects the 400,000 private units owned by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $4,000,000.
- As of the Transaction Date, the reporting person transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
- As of the Transaction Date, pursuant to share transfer agreements, the reporting person transferred an aggregate of 5,698,363 ordinary shares for consideration ranging from no consideration to $1.50 per share.
- The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.
Billionaire Hedge Funds
